Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-453 in Adult Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of surzetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events at 3 years, Maximum Administered Dose of ABBV-453 at 18 months and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
surzetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06291220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291220.